Literature DB >> 7106619

Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice.

G A McPherson, I S Benjamin, A R Boobis, M J Brodie, C Hampden, L H Blumgart.   

Abstract

Antipyrine elimination was studied in 29 patients with obstructive jaundice Antipyrine half-lives calculated using plasma concentrations at four and 24 hours ('short antipyrine test') were significantly correlated with those calculated using six time points (p less than 0.001). Mean antipyrine half-life was 28.3 +/- 8 hours (standard error) and was significantly longer than in normal subjects (p less than 0.001). Antipyrine half-life did not correlate with standard biochemical liver function tests, but correlated positively with the postoperative half-time for clearance of endogenous bilirubin (p less than 0.05), and negatively with hepatic cytochrome P-450 content measured in peroperative liver biopsies (p less than 0.05). Of six patients with antipyrine half-life greater than 20 hours, four died, one preoperatively of gastrointestinal haemorrhage and three postoperatively of sepsis. Serial short antipyrine tests were performed in 13 patients before and after biliary drainage. Those with an initial antipyrine half-life greater than 15 hours showed significant changes after drainage, while those with an antipyrine half-life less than 15 hours did not. The test of antipyrine half-life may aid in selecting high risk patients with obstructive jaundice for percutaneous biliary drainage before definitive surgery, and in determining the optimal time for such preliminary biliary decompression.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106619      PMCID: PMC1419759          DOI: 10.1136/gut.23.9.734

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Disappearance of phenazone from plasma in patients with obstructive jaundice.

Authors:  J Elfström; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

3.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

4.  Drug metabolism in white vegetarians.

Authors:  M J Brodie; A R Boobis; E L Toverud; W Ellis; S Murray; C T Dollery; S Webster; R Harrison
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

5.  Surgical treatment of cancer of the pancreas and the periampullary region: cumulative results in 57 institutions in Japan.

Authors:  A Nakase; Y Matsumoto; K Uchida; I Honjo
Journal:  Ann Surg       Date:  1977-01       Impact factor: 12.969

6.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

7.  Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.

Authors:  A R Boobis; M J Brodie; G C Kahn; D R Fletcher; J H Saunders; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.

Authors:  M J Brodie; A R Boobis; C J Bulpitt; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  8 in total
  8 in total

1.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters.

Authors:  J M Scavone; D J Greenblatt; G T Blyden; J S Harmatz; P J Graziano
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

2.  Low serum testosterone concentrations in carcinoma of the pancreas.

Authors:  K E McColl
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-19

3.  Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.

Authors:  J Wojcicki; K Kozlowski; M Drozdzik; M Wojcicki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

Review 4.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

5.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 6.  A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice.

Authors:  Miguel E Sewnath; Thomas M Karsten; Martin H Prins; Erik J A Rauws; Huug Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

7.  Accuracy and clinical utility of simplified tests of antipyrine metabolism.

Authors:  G C Farrell; L Zaluzny
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

8.  Effect of biliary obstruction and internal biliary drainage on hepatic cytochrome P450 isozymes in rats.

Authors:  Shintaro Fukushima; Hiroyasu Okuno; Nobuyuki Shibatani; Yoshitsugu Nakahashi; Toshihito Seki; Kazuichi Okazaki
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.